TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22907796

Group type: EXPERIMENTAL
Intervention: Intraoperative ice pack application
Number of subjects: 18

Group type: COMPARATOR
Intervention: Room temperature packs
Number of subjects: 18
Study: 19758358

Group type: EXPERIMENTAL
Intervention: Sibutramine and individualized weight management
Number of subjects: 10742
Study: 18656571

Group type: EXPERIMENTAL
Intervention: Knowledge of fruit and vegetable recommendations
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Perceived barriers
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Stage of change (action vs contemplation/preparation)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Perceived health benefits
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Daily servings of fruit and vegetable intake
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Awareness of fruit and vegetable recommendations
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Awareness of colorful variety importance
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Understanding of serving size
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Recognition of fiber source
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Understanding of vitamin pills
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Recognition of health benefits
Number of subjects: 490
Study: 15836935

Group type: EXPERIMENTAL
Intervention: Idiopathic Scoliosis patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy adolescent females)
Number of subjects: 40
Study: 12028852

Group type: EXPERIMENTAL
Intervention: BACCOFF + DIPSTOP
Number of subjects: 22

Group type: COMPARATOR
Intervention: BACCOFF + placebo control
Number of subjects: 22

Group type: COMPARATOR
Intervention: DIPSTOP
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo control only
Number of subjects: 22
Study: 10488712

Group type: EXPERIMENTAL
Intervention: Telomerase activity in hepatocellular carcinoma
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Telomerase activity in adenomatous hyperplasia
Number of subjects: 29

Group type: COMPARATOR
Intervention: Telomerase activity in non-tumorous liver tissue
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Telomerase activity in small tumors (≤2 cm)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Telomerase activity in larger tumors (>2 cm)
Number of subjects: 29
Study: 8706450

Group type: EXPERIMENTAL
Intervention: Active drug (polymerized bovine hemoglobin)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control infusion of lactated Ringer's solution
Number of subjects: 41
Study: 1860763

Group type: EXPERIMENTAL
Intervention: Ionic high-osmolar contrast medium (diatrizoate)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nonionic low-osmolar contrast medium (iopamidol)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single plasma sample at 3 hours
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Two plasma samples
Number of subjects: 100
Study: 6360817

Group type: EXPERIMENTAL
Intervention: Doxorubicin, cyclophosphamide, and cis-platinum
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prostaglandin synthesis inhibitors (acetylsalicyclic acid or indomethacin) during cytostatic infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Patients with residual ovarian cancer
Number of subjects: 19
Study: 30557443

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone
Number of subjects: 570

Group type: COMPARATOR
Intervention: Extended-release naltrexone
Number of subjects: 570
Study: 29985202

Group type: EXPERIMENTAL
Intervention: High-intensity statin, maximally tolerated angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker, and low-dose aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conservative empiric treatment or further diagnostic evaluation of the coronary microvasculature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional antianginal and antiatherosclerotic medications
Number of subjects: 0
Study: 26725287

Group type: EXPERIMENTAL
Intervention: Rehospitalization within three months of index hospitalization
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Rehospitalization
Number of subjects: 373
Study: 26905703

Group type: EXPERIMENTAL
Intervention: Esmolol 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lignocaine 2 mg/kg
Number of subjects: 60
Study: 21726907

Group type: EXPERIMENTAL
Intervention: Taipei Osteoarthritis Program (TOAP) - 4 weeks duration
Number of subjects: 205

Group type: COMPARATOR
Intervention: Routine care (Control Group)
Number of subjects: 205
Study: 19495958

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m(2) weekly
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m(2) weekly
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 300 mg/m(2) q3w
Number of subjects: 300

Group type: COMPARATOR
Intervention: docetaxel 100 mg/m(2) q3w
Number of subjects: 300
Study: 16533865

Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Paroxetine (21 days treatment)
Number of subjects: 2
Study: 16536960

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Non-participants
Number of subjects: 72
Study: 14551680

Group type: COMPARATOR
Intervention: Imipenem/cilastatin for 14 days (group 1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin for at least 14 days (group 2)
Number of subjects: 92
Study: 10896014

Group type: EXPERIMENTAL
Intervention: Aspirin (900 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Codeine (60 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 8938165

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous acetic acid injection (15%, 20%, 30%, 40%, and 50% concentration)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Percutaneous acetic acid injection alone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Percutaneous acetic acid injection after transcatheter arterial embolization
Number of subjects: 28
Study: 1410729

Group type: EXPERIMENTAL
Intervention: ASL 900 mg and meperidine 100 mg/8 h (Group C)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: ASL 900 mg and 1.800 mg/8 h together with meperidine 100 mg/8 h (Group D)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: meperidine 50 mg and 100 mg/8 h (Group G)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: meperidine 50 mg and 100 mg/8 h together with ASL 1.800 mg/8 h (Group H)
Number of subjects: 160

Group type: COMPARATOR
Intervention: ASL 900 mg and 1.800 mg/8 h (Group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: ASL 900 mg and 3.600 mg/8 h (Group B)
Number of subjects: 160

Group type: COMPARATOR
Intervention: meperidine 50 mg and ASL 1.800 mg/8 h (Group E)
Number of subjects: 160

Group type: COMPARATOR
Intervention: meperidine 50 mg and ASL 3.600 mg/8 h (Group F)
Number of subjects: 160
Study: 6731324

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 490

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study: 31725428

Group type: EXPERIMENTAL
Intervention: TAF/FTC/DTG
Number of subjects: 48
Study: 28967706

Group type: EXPERIMENTAL
Intervention: Letermovir 80 mg twice daily for 7 days with CsA 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letermovir 80 mg twice daily for 11 days with TAC 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letermovir 40 mg twice daily for 14 days with CsA 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letermovir 40 mg twice daily for 14 days with CsA 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAC coadministered with letermovir
Number of subjects: 0
Study: 26484738

Group type: EXPERIMENTAL
Intervention: Robotic radiosurgery (single-session, frameless, image-guided); tumor dose of 18-22 Gy (mean 20.3 Gy) prescribed to the 70% isodose line.
Number of subjects: 217
Study: 25294382

Group type: EXPERIMENTAL
Intervention: Outdoor physical activity (quartiles)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Total vitamin D intake (quartiles)
Number of subjects: 419
Study: 22248392

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg daily plus standard care
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care (surgical debridement + culture-specific antibiotics + offloading + glycaemic control)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study: 20404622

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: No BIS monitoring (Control)
Number of subjects: 50
Study: 18623974

Group type: EXPERIMENTAL
Intervention: Ni‐Ti rotary files
Number of subjects: 26

Group type: COMPARATOR
Intervention: Manual stainless steel files
Number of subjects: 26
Study: 16425386

Group type: EXPERIMENTAL
Intervention: BCAA granules
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 11877662

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 140
Study: 10513830

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg + Indapamide 0.625 mg (Per/Ind)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg + Indapamide 0.625 mg (Per/Ind) in ISH subgroup
Number of subjects: 383

Group type: COMPARATOR
Intervention: Both groups (Per/Ind and placebo)
Number of subjects: 383
Study: 8924392

Group type: EXPERIMENTAL
Intervention: Comprehensive education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic instruction
Number of subjects: 0
Study: 1708528

Group type: EXPERIMENTAL
Intervention: Org 10172
Number of subjects: 289

Group type: COMPARATOR
Intervention: dextran 70
Number of subjects: 289
Study: 6181329

Group type: EXPERIMENTAL
Intervention: Endralazine (10-20 mg t.i.d.)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Dihydralazine (25-50 mg t.i.d.)
Number of subjects: 23
Study: 31390073

Group type: EXPERIMENTAL
Intervention: Short video tutorial advising how to help children cope with fearful situations
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 72
Study: 30657853

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 or 10 mg/kg Q3W
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (archival samples)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (newly collected samples)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1033
Study: 29289446

Group type: COMPARATOR
Intervention: Cluster-hole acetabular components
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Solid-backed acetabular components
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Screw group (patients requiring screws for stability)
Number of subjects: 100
Study: 26453968

Group type: EXPERIMENTAL
Intervention: Daclatasvir 30mg plus simeprevir 150mg once daily without ribavirin
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Daclatasvir 30mg plus simeprevir 150mg once daily with ribavirin
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Daclatasvir 30mg plus simeprevir with ribavirin for 24 weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Daclatasvir 30mg plus simeprevir with ribavirin
Number of subjects: 168

Group type: COMPARATOR
Intervention: Daclatasvir 30mg plus simeprevir without ribavirin
Number of subjects: 168
Study: 23544953

Group type: EXPERIMENTAL
Intervention: Web-based parenting intervention based on the Triple P-Positive Parenting Programme
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 39
Study: 22018509

Group type: EXPERIMENTAL
Intervention: 1 g DHA-rich fish oil
Number of subjects: 22

Group type: COMPARATOR
Intervention: 1 g EPA-rich fish oil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (1 g olive oil)
Number of subjects: 22
Study: 19597169

Group type: EXPERIMENTAL
Intervention: HIOH delivered in the home
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: HIOH delivered by telephone
Number of subjects: 415

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study: 17052816

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine
Number of subjects: 46
Study: 16508679

Group type: COMPARATOR
Intervention: Conventional fractionation radiotherapy (CF) (5 fractions per week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiotherapy (AF) (6 fractions per week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AF plus Mitomycin C (MMC)
Number of subjects: 60
Study: 11986501

Group type: EXPERIMENTAL
Intervention: Empirically validated skills training program for self-management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 9818496

Group type: EXPERIMENTAL
Intervention: Vitex agnus castus (VACS) extract, 2 x 30 drops/day for 3 menstrual cycles
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 7862879

Group type: EXPERIMENTAL
Intervention: Caffeine (178 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Theobromine (560 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 2492454

Group type: EXPERIMENTAL
Intervention: t‐PA (1.5 mg/kg/4 hr) and heparin (10,000 units bolus)
Number of subjects: 134

Group type: COMPARATOR
Intervention: t‐PA (1.5 mg/kg/4 hr) only
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: t‐PA and heparin
Number of subjects: 134

Group type: COMPARATOR
Intervention: t‐PA only
Number of subjects: 134
Study: 1095107

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Carbenicillin indanyl ester
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nifuratel
Number of subjects: 120

Group type: COMPARATOR
Intervention: Penicillin drugs (control group)
Number of subjects: 120
Study: 31670790

Group type: EXPERIMENTAL
Intervention: Low-dose acupuncture (DP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-dose acupuncture (DPTN)
Number of subjects: 28
Study: 30623408

Group type: EXPERIMENTAL
Intervention: PAC‐14028 cream 0·1%
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: PAC‐14028 cream 0·3%
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: PAC‐14028 cream 1·0%
Number of subjects: 194

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 194
Study: 27464957

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (TM) with oximetry, temperature, pulse, electrocardiogram, blood pressure, spirometry, and weight monitoring, along with telephone support and home visits
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group receiving only identical telephone support and home visits
Number of subjects: 42
Study: 26415793

Group type: EXPERIMENTAL
Intervention: 6, 8, 10, 12, or 14 mg intrathecal hyperbaric ropivacaine with 5 μg sufentanil
Number of subjects: 75
Study: 22535635

Group type: EXPERIMENTAL
Intervention: Standard dialysis therapy with constant ultrafiltration (UF) rate, cool dialysate and high sodium conductivity (Treatment A)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Dialysis regimens with adjunctive interventions including blood volume (BV) control (Treatment B)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Dialysis regimens with the combination of BV and active blood temperature control (Treatment C)
Number of subjects: 74

Group type: COMPARATOR
Intervention: All treatments (A, B, C)
Number of subjects: 74
Study: 21762628

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus oxaliplatin (GO)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 66
Study: 19147343

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision with preoperative radiotherapy (PRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total mesorectal excision without preoperative radiotherapy (PRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision with or without preoperative radiotherapy (PRT)
Number of subjects: 0
Study: 16749917

Group type: EXPERIMENTAL
Intervention: Aloe vera (AV)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 15072869

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 160 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propionyl‐L‐carnitine 2 g/day plus acetyl‐L‐carnitine 2 g/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 120
Study: 15230299

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10511349

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 127
Study: 8524560

Group type: EXPERIMENTAL
Intervention: Monitoring by community optometrists
Number of subjects: 8
Study: 2107926

Group type: EXPERIMENTAL
Intervention: Tacrine (mean of 114 mg daily) and lecithin (1200 mg daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo and lecithin (1200 mg daily)
Number of subjects: 67
Study: 395519

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mestranol with norethynodrel (Enavid, Searle)
Number of subjects: 0
Study: 30235949

Group type: EXPERIMENTAL
Intervention: music-with-movement intervention
Number of subjects: 165

Group type: COMPARATOR
Intervention: music listening
Number of subjects: 165

Group type: COMPARATOR
Intervention: social activities
Number of subjects: 165
Study: 30933384

Group type: EXPERIMENTAL
Intervention: 980‐nm diode laser (DL) irradiation in combination with mechanical therapy (setting 980 nm, 2.5 W, 10 kHz, pw, 30 s)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Mechanical debridement using curettes and ultrasonic devices
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both therapeutic modalities
Number of subjects: 220
Study: 29072018

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment using the Midnight-noon Ebb-flow method combined with syndrome differentiation for 3 months
Number of subjects: 136

Group type: COMPARATOR
Intervention: Routine treatment for language rehabilitation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 136
Study: 25808378

Group type: EXPERIMENTAL
Intervention: Gradually increasing retraction force
Number of subjects: 12

Group type: COMPARATOR
Intervention: Relatively constant continuous retraction force
Number of subjects: 12
Study: 24684757

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 450
Study: 22867630

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study: 19616195

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 62
Study: 17612947

Group type: EXPERIMENTAL
Intervention: Morning cycling exercise at 45 W and 80% of T(vent)
Number of subjects: 14
Study: 15558995

Group type: COMPARATOR
Intervention: Control (seated rest for 15 min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Active warming (cycling ergometry for 15 min at 70% Vo2 peak)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Passive warming (immersion in a circulated bath at 40 degrees C)
Number of subjects: 7
Study: 12057066

Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b (HDI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin-2 based biochemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shorter courses of HDI or vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate-dose interferon
Number of subjects: 0
Study: 9635714

Group type: COMPARATOR
Intervention: 6 cycles of CCNU, vinblastine, procarbazine, and prednisone (CVPP)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 12 cycles of CVPP
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 6 cycles of CVPP followed by 25 Gy radiotherapy
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 3 cycles CVPP, 25 Gy radiotherapy, and 3 cycles CVPP
Number of subjects: 258
Study: 8605053

Group type: EXPERIMENTAL
Intervention: Rifabutin prophylaxis
Number of subjects: 1146
Study: 2562473

Group type: EXPERIMENTAL
Intervention: Inhaled ouabain (doses ranged from 50 micrograms to 5000 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30500925

Group type: EXPERIMENTAL
Intervention: E-cigarette sampling (weekly supply for 3 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E-cigarette sampling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no e-cigarette sampling)
Number of subjects: 0
Study: 30025415

Group type: EXPERIMENTAL
Intervention: NER1006
Number of subjects: 515

Group type: COMPARATOR
Intervention: SP+MC
Number of subjects: 515
Study: 28031390

Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 24166893

Group type: EXPERIMENTAL
Intervention: Calcium 2 g
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vitamin D3 800 IU/d
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Calcium 2 g and Vitamin D3 800 IU/d
Number of subjects: 92
Study: 25041370

Group type: EXPERIMENTAL
Intervention: Modified Alt-RAMEC/FM protocol
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: RME/FM protocol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Untreated Class III malocclusion (control group)
Number of subjects: 31
Study: 21507018

Group type: EXPERIMENTAL
Intervention: Inter-group comparative context manipulation in Study 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inter-group comparative context manipulation in Study 2
Number of subjects: 0